The Effect of Modified Sini Decoction on Survival Rates of Patients with Hepatitis B Virus Related Acute-on-Chronic Liver Failure

Table 1

Baseline characteristics.

Characteristics	Observation group	Control; group	t/χ^2	P-value
Age (years)	41.7 ± 9.9	42.5 ± 10.2	1.341	0.381
Males (%)	43(69.4)	35(70.0)	0.005	0.941
ALT (U/L)	438.5 ± 85.8	456.9 ± 89.6	0.594	0.618
AST (U/L)	401.7 ± 78.5	410.7 ± 86.3	0.641	0.431
TBIL (umol /L)	356.3 ± 80.5	347.6 ± 78.1	0.684	0.513
PTA (%)	17.1 ± 2.4	16.7 ±3.2	0.298	0.701
ALB (g/L)	26.1 ± 6.4	26.7 ±6.0	0.562	0.487
Creatinine (umol/L)	72.3 ± 15.1	69.6 ± 12.9	1.270	0.301
Sodium (mmol/L)	130.9 ± 38.3	129.1 ± 40.5	1.615	0.231
CTP points	12.2 ± 1.7	13.0 ± 2.3	1.304	0.209
MELD points	28.9 ± 5.1	26.7 ± 4.9	0.732	0.809
HBeAg-positive (%)	21 (33.9)	18 (36.0)	0.055	0.814
HBV-DNA; (log10 copies/mL)	6.4 ± 1.3	6.7 ± 1.8	0.781	0.512
Ascites (%)	50 (80.6)	37 (74.0)	0.705	0.401
Hepatic encephalopathy(II-IV) (%)	22 (35.5)	17 (34.0)	0.027	0.870
Severe infection (%)	16 (25.8)	13 (26.0)	0.001	0.981
Hemorrhage of upper gastrointestinal tract (%)	21 (33.9)	18 (36)	0.055	0.814
Hepatorenal syndrome (%)	6 (9.7)	5 (10.0)	0.003	0.955

All values are expressed as mean ± SD or number (%).